Syndax

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, that focuses on developing innovative therapies for various cancer types. The company’s lead product candidate, entinostat, is a class I HDAC inhibitor currently in Phase III clinical trials for advanced hormone receptor-positive, HER2-negative breast cancer. Additionally, Syndax is developing SNDX-5613, a selective inhibitor targeting the Menin-MLL interaction, for acute leukemias, and SNDX-6352, a monoclonal antibody aimed at the CSF-1 receptor, for chronic graft-versus-host disease. The company is also exploring combination therapies involving entinostat with checkpoint inhibitors like Keytruda and Tecentriq for lung cancer and metastatic breast cancer. Syndax has established collaborations with various pharmaceutical companies and research institutions to support its clinical development efforts. Founded in 2005, Syndax aims to enhance treatment options for patients with solid tumors and hematological cancers through its diverse pipeline.